NCT05873205 is a Phase 2 clinical trial of Isatuximab in Blood Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT05873205?

NCT05873205 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT05873205?

Interventions in NCT05873205: Isatuximab.

What condition does NCT05873205 study?

NCT05873205 studies Blood Cancer, Refractory Immune Cytopenias.

Is NCT05873205 still recruiting?

NCT05873205 is currently active, enrolled. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT05873205

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

Active, enrolled Phase 2 Last updated 2 April 2026

What this trial tests

Phase 2 trial testing Isatuximab in Blood Cancer in 12 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

21 July 2023

Primary endpoint
29 June 2027

29 June 2027

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	21 July 2023
Primary completion	29 June 2027
Estimated completion	29 June 2027
Sites	7 locations across United States

Drugs / interventions tested

Isatuximab (isatuximab) — full drug profile →

Conditions studied

Blood Cancer — all drugs for Blood Cancer →
Refractory Immune Cytopenias — all drugs for Refractory Immune Cytopenias →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Blood Cancer or Refractory Immune Cytopenias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Isatuximab

Trials testing the same drug.

NCT07045909 — Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) · Phase 2 · recruiting
NCT05862766 — Isatuximab in Lung Transplant Recipients · EARLY_PHASE1 · withdrawn
NCT05922501 — Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
NCT06182774 — Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Mu · Phase 3 · recruiting
NCT06203912 — Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma · Phase 1 · active not recruiting

Other recruiting trials for Blood Cancer

Currently open trials in the same condition.

NCT06904066 — Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W · Phase 1 · recruiting
NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
NCT07305090 — Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Ve · recruiting
NCT07052916 — A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties · NA · recruiting
NCT06510699 — Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial · Phase 2 · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05873205 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05873205.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing